Concurrent work by Molgora et al. demonstrated the critical role of triggering receptor expressed on myeloid cells (TREM2) in immunosuppression in various human cancers and provided strong evidence that TREM2 is a viable therapeutic target to reshape immunosuppressive TAMs to anti-tumoral effects by improving the efficacy of checkpoint blockade therapy [14]. Here, TREM2 is linked to cancer.